Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective StudyShigeo Shimose, Takuji Torimura, Hironori Koga et al.|Cancers|2020Cited by 78
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysisShigeo Shimose, Takuji Torimura, Takumi Kawaguchi et al.|Oncology Letters|2020Cited by 64
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching StudyShigeo Shimose, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2021Cited by 57
Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort StudyShigeo Shimose, Takuji Torimura, Takumi Kawaguchi et al.|Nutrients|2020Cited by 47
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinomaShigeo Shimose, Takumi Kawaguchi, Atsushi Hiraoka et al.|Hepatology Research|2022Cited by 31